Providence Health Care and partners team up with China’s BGI to Accelerate Precision Medicine
Submitted by St. Paul's Foundation
Providence Health Care has teamed up leading health and research organizations in British Columbia and the world’s largest genomics organization, based in China, forming a global partnership to bring together advanced technologies and individualized therapy for cancer and other diseases.
The partnership, between Shenzhen-based BGI, Providence Health Care, St. Paul’s Foundation, Vancouver Prostate Centre (VPC), Genome British Columbia (Genome BC), and Deloitte Inc., focuses on applying next generation sequencing technologies and big data to accelerate personalized medicine and improve outcomes for patients.
“This partnership links the best researchers in British Columbia and China with cutting edge genomic technologies to share expertise and accelerate innovation on a global scale,” said Dianne Doyle, President and CEO, Providence Health Care. “Our mutual goal is more effective treatments for patients using precision medicine.”
The collaboration aims to leverage each partner’s strengths to create health centres of excellence in both Shenzhen and Vancouver. Cooperative research programs will build on BC’s capability for world-class genomics research and BGI’s internationally recognized expertise in ‘omics’ technology, data analysis and research.
A Memorandum of Understanding was signed by the parties at a ceremony at the Vancouver Board of Trade during the American Society of Human Genetics 2016 annual meeting.
The partners envision creating a joint research centre at the new St. Paul’s Hospital campus that would involve scientists and clinicians from UBC’s Faculty of Medicine and use BGI’s cost-effective, high-throughput sequencing capabilities. Deloitte will contribute its expertise managing the big data analytics environment to facilitate world class research and enable health information to be securely shared with the various research partners.
BGI, the world’s largest genomics organization, began a partnership with the VPC earlier this year for a BGI-VPC Joint Research Laboratory to combine BGI’s advanced and cost-effective technologies, and VPC’s world class cancer research and drug development program. The partnership focuses on individualized therapy for cancer through evidence-based precision oncology and clinical trials, as well as commercialization for diagnostics and treatment of prostate and others cancers, such as non-invasive “liquid biopsies” for monitoring men with advanced prostate cancer.
Another collaboration is a health economic analysis of personalized medicine, currently being conducted by BGI and the Centre for Health Evaluation and Outcome Sciences (CHEOS). The goal is to develop an economic assessment of sequencing based non-invasive prenatal testing, and an early detection test for cancer, and share the findings in peer reviewed journals, with a strategy to help disseminate information about the technology to health plan sponsors and insurance carriers worldwide.
ALSO IN THIS ISSUE
- Check-in to Win
- Dr. Rachelle Bernacki to host special rounds on Serious Illness Care Conversations
- VIDEO: Physicians and clinicians provide input on new clinical information system
- Measuring the effectiveness of Patient and Family Centred Care at Providence
- How much do you know about the procedures performed at MSJ's Providence Breast Centre?
- Get ready for patient safety week!
- The results of the Staff Sick Time Survey are in!
- Volunteer Resources World Food Day Initiative 2016
- It’s Autumn Bike to Work Week next week (October 24 to 30), and we want to see you on your bike!
- Tips For Making New Habits Stick
- Leadership Program for Physicians and Leaders in Long Term Care - early bird pricing ends soon!
- HEARR Webinar - Finding Compassionate Care in the Face of Violence: Caring for Patients who Cause us Harm
- Looking for a winner every two weeks!